Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

GlobalData tracks 40 years of innovation in FDA review designations

Regulatory authorities, particularly the US FDA, have played a crucial role in accelerating and incentivizing the development of innovative treatments through review designations. Since the first designation in 1984, the FDA has seen a substantial rise in the number of designations granted, reaching 694 in 2020. This surge reflects key pharmaceutical milestones, including the biotech […]
Read more

Intra-Cellular Therapies acquisition will expand Johnson & Johnson’s presence in neurology space, says GlobalData

Johnson & Johnson (J&J) recently announced the acquisition of Intra-Cellular Therapies, a biopharmaceutical company specializing in the development of treatments targeting complex psychiatric and neurological disorders. The deal is the biggest biotech M&A transaction since 2023. As part of the acquisition, J&J will obtain Intra-Cellular’s extensive neurology portfolio, which will allow them to grow its […]
Read more

AstraZeneca’s Fasenra set to revolutionize COPD treatment as Phase III data builds anticipation, says GlobalData

AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 J.P. Morgan Healthcare Conference, is set to transform the chronic obstructive pulmonary disease (COPD) treatment. As the first IL-5-targeting monoclonal antibody in late-stage trials, Fasenra targets eosinophilic inflammation, potentially reshaping treatment standards and reinforcing AstraZeneca’s leadership in respiratory and […]
Read more

GLP-1R gold rush: Emerging biotechs set to challenge market leaders, says GlobalData

The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in sales, with Novo Nordisk and Eli Lilly dominating the sector. However, emerging biotech companies are poised to disrupt this landscape, with promising pipeline products expected to generate substantial revenue and challenge the market leaders by 2030, says GlobalData, a leading […]
Read more

AI is set to improve R&D productivity and lower the costs, says GlobalData

Artificial intelligence (AI) has the potential to significantly reduce pharmaceutical R&D costs by streamlining drug discovery, optimizing clinical trials, and minimizing costly failures through data-driven predictions and effectiveness assessments. This potential was acknowledged by the pharmaceutical industry professionals in a survey* conducted by GlobalData, a leading data and analytics company. GlobalData’s report, “The State of […]
Read more

Ultra-long acting GLP-1R agonists to become future therapeutic options for obesity, says GlobalData

At present, the obesity market is dominated by once-weekly, subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), and in the case of Eli Lilly’s Zepbound/Mounjaro (tirzepatide), also the gastric inhibitory peptide receptor (GIPR). Although most patients seem to be satisfied with the currently available medicines, a weekly injection can sometimes be a burden […]
Read more

Novartis gene therapy poised to expand SMA treatment landscape, says GlobalData

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in a Phase III STEER study (NCT05089656) involving pediatric patients aged 2–17 years with type II spinal muscular atrophy (SMA). These positive results have the potential to broaden the eligible patient population for this gene transfer […]
Read more

Immuno-oncology/ cancer therapeutics present strongest innovation pipeline in next five years, says GlobalData

Immuno-oncology (IO) drugs/ cancer therapeutics represent one of the most promising areas of medical innovation in the next five years, fundamentally transforming how cancer is treated, according to a survey conducted by GlobalData, a leading data and analytics company. In a recent GlobalData’s survey, “The State of the Biopharmaceutical Industry – 2025,” the largest proportion […]
Read more

Eli Lilly’s Zepbound holds potential to dominate obesity market, says GlobalData

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData, a leading data and analytics company. Recently, Eli Lilly announced […]
Read more

Zorifer poised to fill critical gap in treatment of advanced NSCLC with CNS metastases in China, says GlobalData

China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. Developed by Alpha Biopharma in collaboration with AstraZeneca, this new treatment option is expected to benefit EGFR-mutated NSCLC patients with different […]
Read more

Targeted therapies and improved diagnostics remain as unmet needs in T2-low asthma, says GlobalData

Despite advances in biologic therapies for severe asthma, significant unmet needs in asthma management remain, specifically with T-helper cell type 2 (T2)-low asthma, a subtype lacking typical inflammatory biomarkers. T2-low asthma presents unique challenges due to the absence of eosinophils and immunoglobulin E (IgE), which complicates both diagnosis and treatment. Insights from experts in the […]
Read more
1 … 12 13 14 15 16 … 110